Evidence map›Paper›PMID 39967449›Full record

ArticleJournal of radiation research2025

Systemic inflammation response index predicts overall survival in patients undergoing stereotactic radiosurgery for brain metastasis from non-small cell lung cancer.

Ryosuke Matsuda, Tetsuro Tamamoto, Nobuyoshi Inooka, Shigeto Hontsu, Akihiro Doi, Ryosuke Maeoka, Tsutomu Nakazawa, Takayuki Morimoto, Kaori Yamaki, Sachiko Miura and 6 more

Abstract read
In one paragraph

Article in Journal of radiation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Association between the systemic inflammation response index and prognosis in lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ryosuke MatsudaDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Tetsuro TamamotoDepartment of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Nobuyoshi InookaDepartment of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Shigeto HontsuDepartment of Respiratory Medicine, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Akihiro DoiDepartment of Internal Medicine, Heisei Memorial Hospital, 827 Shijo-cho, Kashihara, Nara 634-0813, Japan.
Ryosuke MaeokaDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Tsutomu NakazawaDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Takayuki MorimotoDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Kaori YamakiDepartment of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Sachiko MiuraDepartment of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Yudai MorisakiDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Shohei YokoyamaDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Masashi KotsugiDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Yasuhiro TakeshimaDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Fumiaki IsohashiDepartment of Radiation Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.
Ichiro NakagawaDepartment of Neurosurgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the prognostic value of pre-treatment blood cell counts in patients with brain metastasis (BM) from non-small cell lung cancer (NSCLC) who were treated using linear accelerator (linac)-based stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) with a micro-multileaf collimator. Between January 2011 and November 2022, 271 consecutive patients underwent linac-based SRS/fSRT for BM from NSCLC. Thirty patients with insufficient blood test data during this period were excluded from this analysis. Thirty-five patients with steroid intake at the time point of the blood test and 18 patients with higher C-reactive protein were excluded. Thus, 188 patients were eventually enrolled in this study. The median follow-up period after SRS/fSRT was 21 months (range: 0-121 months), and the median survival time after SRS/fSRT was 19 months. Neutrophil-lymphocyte ratio ≥ 1.90, lymphocyte-monocyte ratio ≤ 1.67 and systemic inflammation response index (SIRI) ≥ 2.95 were unfavorable predictors of prognosis for patients who underwent SRS/fSRT for BM from NSCLC. Cox proportional-hazard multivariate analysis revealed that the SIRI was independent prognostic factors for increased risk of death. Thus, simple, less expensive, and routinely performed pre-treatment blood cell count measurements such as SIRI can predict the overall survival of patients treated with SRS/fSRT for BM from NSCLC.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungInflammationLung NeoplasmsRadiosurgeryAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsSurvival Analysisbrain metastasisneutrophil–lymphocyte rationon-small cell lung cancersystemic immune-inflammation indexsystemic inflammation response index

Identifiers

PMID39967449
PMCPMC11932349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.